PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIron dextran
Iron dextran
Ferric Oxyhydroxide, Ferrlecit, Infed, Velphoro, Venofer (iron dextran) is an unknown pharmaceutical. Iron dextran was first approved as Infed on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
ferrlecitNew Drug Application2025-06-06
infedNew Drug Application2024-10-14
iron dextranNew Drug Application2025-01-08
venoferNew Drug Application2022-07-25
venofer (iron sucrose)New Drug Application2024-04-19
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ferric Oxyhydroxide, Velphoro, Vifor Fresenius
106248552034-11-26DP
112349382034-11-26DP
114462522034-11-26DP
95612512030-01-23DPU-1468
106823762028-11-13DP
106953672028-11-13DP
109258962028-11-13DP
109258972028-11-13DP
109330902028-11-13DP
110137612028-11-13DP
110137622028-11-13DP
ATC Codes
No data
HCPCS
Code
Description
J1750
Injection, iron dextran, 50 mg
Clinical
Clinical Trials
2369 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron overloadD019190——217714644
ThalassemiaD013789EFO_1001996D561949225
Myelodysplastic syndromesD009190—D46—11—6320
PreleukemiaD011289———9—6318
Beta-thalassemiaD017086Orphanet_848D56.11635116
SyndromeD013577———7—6215
AnemiaD000740EFO_0004272D64.91515214
HemochromatosisD006432EFO_1000642E83.111624113
HemosiderosisD006486——1624113
Sickle cell anemiaD000755EFO_0000697D57—32139
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95111——2
Myeloid leukemiaD007951—C92111——2
Porphyria cutanea tardaD017119—E80.1——1——1
Erythropoietic porphyriaD017092————1——1
PorphyriasD011164EFO_0000665———1——1
Hepatic porphyriasD017094————1——1
Primary myelofibrosisD055728—D47.4——1——1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340———1——1
Philadelphia chromosomeD010677————1——1
Hepatitis bD006509————1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MucormycosisD009091EFO_0007380B46.5—1———1
ZygomycosisD020096—B46—1———1
Hemolytic anemiaD000743—D55-D59—1———1
Fanconi anemiaD005199Orphanet_84D61.03—1———1
Fanconi syndromeD005198———1———1
Myeloid leukemia acuteD015470—C92.011———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD048550——1————1
Iron-deficiency anemiaD018798—D501————1
Iron deficienciesD000090463—E61.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytopeniaD013921HP_0001873D69.6————11
Liver cirrhosisD008103EFO_0001422K74.0————11
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81————11
Fatty liverD005234EFO_0003934—————11
Myelomonocytic leukemia chronicD015477—C93.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIron dextran
INN—
Description
Iron supplements, also known as iron salts and iron pills, are a number of iron formulations used to treat and prevent iron deficiency including iron deficiency anemia. For prevention they are only recommended in those with poor absorption, heavy menstrual periods, pregnancy, hemodialysis, or a diet low in iron. Prevention may also be used in low birth weight babies. They are taken by mouth, injection into a vein, or injection into a muscle. While benefits may be seen in days, up to two months may be required until iron levels return to normal.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID10028-22-5
RxCUI—
ChEMBL IDCHEMBL1201544
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Iron dextran
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,529 documents
View more details
Safety
Black-box Warning
Black-box warning for: Iron dextran
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
9,774 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use